Melatonin as an angiogenesis inhibitor to combat cancer: Mechanistic evidence

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Melatonin, a pineal indolamine, exhibits anti-tumor properties.
• Angiogenesis, the formation of new blood vessels, is crucial for tumor progression.
• Inhibiting angiogenesis is a critical strategy in cancer therapy.

Purpose of the Study:

• To review the molecular mechanisms by which melatonin inhibits angiogenesis.
• To explore melatonin's anti-angiogenic pathways in various cancer models.
• To consolidate understanding of melatonin's oncostatic effects via angiogenesis inhibition.

Main Methods:

• Review of molecular anti-angiogenesis pathways mediated by melatonin.
• Analysis of melatonin's effects on hypoxia-induced factor-1α (HIF-1α) and vascular endothelial growth factor (VEGF) expression.
• Examination of melatonin's impact on endothelial cell functions and receptor activation (e.g., VEGFR2).

Main Results:

• Melatonin inhibits angiogenesis by targeting HIF-1α nuclear translocation and downstream gene expression, including VEGF.
• It disrupts the formation of protein complexes essential for angiogenesis-related gene expression.
• Melatonin also inhibits endothelial cell migration, invasion, and tube formation, and affects VEGFR2 activation.

Conclusions:

• Melatonin exerts significant anti-angiogenic effects through multiple molecular pathways.
• These mechanisms contribute to melatonin's oncostatic action in various cancer types.
• Understanding these pathways can inform the development of novel cancer therapies utilizing melatonin.